NLRP3炎性小体在脑缺血再灌注中的作用

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (1): 120-124.

NLRP3炎性小体在脑缺血再灌注中的作用

郭艳芹, 殷博凯, 张娟, 何治^*

三峡大学医学院, 湖北宜昌 443002

收稿日期:2019-12-05 修回日期:2020-03-26 出版日期:2021-01-05 发布日期:2020-12-30
通讯作者: ^*hezhi2003@163.com
基金资助:
天然产物研究与利用湖北省重点实验室开放基金(NPRD-2018001); 2020年三峡大学研究生学位论文培优基金(2020SSPY106)

Effect of NLRP3 inflammasome on cerebral ischemia-reperfusion

GUO Yan-qin, YIN Bo-kai, ZHANG Juan, HE Zhi^*

Medical College of Three Gorges University,Yichang 443002,China

Received:2019-12-05 Revised:2020-03-26 Online:2021-01-05 Published:2020-12-30
Contact: ^*hezhi2003@163.com

摘要/Abstract

摘要： NLRP3炎性小体是一种结构复杂、调控机制尚不明确的多蛋白复合体,它的过度活化涉及多个系统疾病的病理生理过程。脑缺血(CI)作为发病率最高的脑血管疾病,由于对其溶栓治疗的应用受限,因而开发CI后神经保护药物尤为重要。寻求有效的药物靶点可能为脑缺血再灌注损伤(CIRI)提供新的治疗思路。

关键词: 脑缺血再灌注, NLRP3炎性小体, 活化, 负向调控

Abstract: NLRP3 inflammasome is a polyprotein complex with complicated structure and unknown regulatory mechanism. Excessive activation of NLRP3 inflammasome is believed to be related to pathophysiological processes with multiple systemic diseases. Cerebral ischemia is the cerebrovascular disease with the highest incidence. Due to the limited application of thrombolytic therapy, it is particularly important to develop neuroprotective drugs after cerebral ischemia. Identification effective drug targets may provide new approaches in the treatment of cerebral ischemia-reperfusion injury(CIRI).

Key words: cerebral ischemia-reperfusion, NLRP3 inflammasome, activation, negative regulation

中图分类号:

R743

郭艳芹, 殷博凯, 张娟, 何治. NLRP3炎性小体在脑缺血再灌注中的作用[J]. 基础医学与临床, 2021, 41(1): 120-124.

GUO Yan-qin, YIN Bo-kai, ZHANG Juan, HE Zhi. Effect of NLRP3 inflammasome on cerebral ischemia-reperfusion[J]. Basic & Clinical Medicine, 2021, 41(1): 120-124.

参考文献

[1] Afonina IS, Zhong Z, Karin M, et al. Limiting inflammation-the negative regulation of NF-kappaB and the NLRP3 inflammasome[J]. Nat Immunol, 2017,18:861-869.
[2] Zhao J, Wang J, Zhou M, et al. Curcumin attenuates murine lupus via inhibiting NLRP3 inflammasome[J]. Int Immunopharmacol, 2019,69:213-216.
[3] Chen H, Lin H, Xie S, et al. Myricetin inhibits NLRP3 inflammasome activation via reduction of ROS-dependent ubiquitination of ASC and promotion of ROS-independent NLRP3 ubiquitination[J]. Toxicol Appl Pharmacol, 2019,365:19-29.
[4] Deng Q, Geng Y, Zhao L, et al. NLRP3 inflammasomes in macrophages drive colorectal cancer metastasis to the liver[J]. Cancer Lett, 2019,442:21-30.
[5] Qi Y, Klyubin I, Cuello AC, et al. NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo[J]. Neurobiol Dis, 2018,114:24-30.
[6] Zhang S, Jiang L, Che F, et al. Arctigenin attenuates ischemic stroke via SIRT1-dependent inhibition of NLRP3 inflammasome[J]. Biochem Biophys Res Commun, 2017,493:821-826.
[7] Martin-Sanchez F, Martinez-Garcia JJ, Munoz-Garcia M, et al. Lytic cell death induced by melittin bypasses pyroptosis but induces NLRP3 inflammasome activation and IL-1beta release[J]. Cell Death Dis, 2017,8:e2984. doi: 10.1038/cddis.2017.390.
[8] de Carvalho R, Andrade WA, Lima-Junior DS, et al. Leishmania lipophosphoglycan triggers caspase-11 and the non-canonical activation of the NLRP3 inflammasome[J]. Cell Rep, 2019,26:429-437.
[9] Dabo S, Maillard P, Collados RM, et al. Inhibition of the inflammatory response to stress by targeting interaction between PKR and its cellular activator PACT[J]. Sci Rep, 2017,7:16129.doi: 10.1038/s41598-017-16089-8.
[10] Jiang Y, Steinle JJ. Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells[J]. J Inflamm Res, 2019,12:153-159.
[11] Shenoy AR, Wellington DA, Kumar P, et al. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals[J]. Science, 2012,336:481-485.
[12] Man SM, Karki R, Sasai M, et al. IRGB10 liberates bacterial ligands for sensing by the AIM2 and caspase-11-NLRP3 inflammasomes[J]. Cell, 2016,167:382-396.
[13] He Y, Zeng MY, Yang D, et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux[J]. Nature, 2016,530:354-357.
[14] Liu X, Zhang X, Ding Y, et al. Nuclear factor E2-related factor-2 negatively regulates NLRP3 inflammasome activity by inhibiting reactive oxygen species-induced NLRP3 priming[J]. Antioxid Redox Signal, 2017,26:28-43.
[15] Desai A, Singh N, Raghubir R. Neuroprotective potential of the NF-kappaB inhibitor peptide IKK-NBD in cerebral ischemia-reperfusion injury[J]. Neurochem Int, 2010,57:876-883.
[16] Zhao J, Wang H, Dong L, et al. miRNA-20b inhibits cerebral ischemia-induced inflammation through targeting NLRP3[J]. Int J Mol Med, 2019,43:1167-1178.
[17] Ismael S, Zhao L, Nasoohi S, et al. Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke[J]. Sci Rep, 2018,8:5971.doi: 10.1038/s41598-018-24350-x.
[18] Ito M, Shichita T, Okada M, et al. Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury[J]. Nat Commun, 2015,6:7360.doi: 10.1038/ncomms8360.
[19] Jiang H, He H, Chen Y, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders[J]. J Exp Med, 2017,214:3219-3238.
[20] Samir P, Kesavardhana S, Patmore DM, et al. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome[J]. Nature, 2019,573:590-594.
[21] Chen H, Lin H, Xie S, et al. Myricetin inhibits NLRP3 inflammasome activation via reduction of ROS-dependent ubiquitination of ASC and promotion of ROS-independent NLRP3 ubiquitination[J]. Toxicol Appl Pharmacol, 2019,365:19-29.
[22] Kim SK, Choe JY, Park KY. Anti-inflammatory effect of artemisinin on uric acid-induced NLRP3 inflammasome activation through blocking interaction between NLRP3 and NEK7[J]. Biochem Biophys Res Commun, 2019,517:338-345.
[23] Hughes MM, Hooftman A, Angiari S, et al. Glutathione transferase Omega-1 regulates NLRP3 inflammasome activation through NEK7 deglutathionylation[J]. Cell Rep, 2019,29:151-161.
[24] Chen X, Zhou Y, Yu J. Exosome-like nanoparticles from Ginger Rhizomes inhibited NLRP3 inflammasome activa-tion[J]. Mol Pharm, 2019,16:2690-2699.